In a report released on October 10, Michael Okunewitch from Maxim Group maintained a Buy rating on Mainz Biomed B.V., with a price target of $14.00.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Michael Okunewitch has given his Buy rating due to a combination of factors, including promising new data from Mainz Biomed’s PancAlert feasibility study. The study demonstrated high diagnostic accuracy, achieving 100% sensitivity and 95% specificity in detecting pancreatic cancer and precancerous lesions. This capability is crucial for early intervention, which significantly improves patient survival rates.
Additionally, despite recent financial challenges, Mainz Biomed is positioned for potential growth with upcoming data from the eAArly DETECT 2 study for colorectal cancer. The collaboration with Liquid Biosciences further strengthens their pipeline, offering a promising blood-based screening program for pancreatic cancer. These developments suggest a positive outlook for the company’s stock, justifying the Buy rating.
According to TipRanks, Okunewitch is a 2-star analyst with an average return of 0.1% and a 41.10% success rate. Okunewitch covers the Healthcare sector, focusing on stocks such as Lineage Therap, ATAI Life Sciences, and Ocugen.